Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes

Autor:	Gregory G. Schwartz, Peter Ganz, David D. Waters, Steven R. Arikian
Rok vydání:	2003
Předmět:	medicine.medical_specialty Acute coronary syndrome Cost-Benefit Analysis Atorvastatin Myocardial Infarction Myocardial Ischemia Ischemia MIRACL Placebo health services administration Internal medicine Secondary Prevention Humans Medicine Pyrroles heterocyclic compounds Angina Unstable Economics Pharmaceutical cardiovascular diseases business.industry Vascular disease nutritional and metabolic diseases Health Care Costs Syndrome Direct cost medicine.disease Heptanoic Acids Acute Disease Circulatory system Cardiology lipids (amino acids peptides and proteins) Hydroxymethylglutaryl-CoA Reductase Inhibitors Cardiology and Cardiovascular Medicine business medicine.drug
Zdroj:	The American Journal of Cardiology. 92:1109-1112
ISSN:	0002-9149
DOI:	10.1016/j.amjcard.2003.06.009
Popis:	An economic analysis was conducted using clinical outcomes in the MIRACL trial that evaluated high-dose atorvastatin versus placebo for 16 weeks after acute coronary syndrome. The direct cost of atorvastatin was largely offset by the associated decrease in cardiovascular events. The net incremental cost of atorvastatin treatment was 157 dollars/patient with a cost-effectiveness ratio of 4,086 dollars/event avoided.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::680b96c2598f9ac3bbf72fd736581f89 https://doi.org/10.1016/j.amjcard.2003.06.009 Zobrazit plný text záznamu Full Text from ScienceDirect